NASDAQ · Biotechnology

Eupraxia Pharmaceuticals Inc. (EPRX) Stock

$7.46 -1.45% NASDAQ: EPRX Healthcare

Valuation

MetricValue
Price$7.46
Market Cap$249.76M
P/E Ratio-7.10
P/B Ratio3.66
P/S Ratio0.00
EPS (TTM)$-1.05
52-Week High$9.32
52-Week Low$5.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-45.29%
ROA-35.72%
ROCE-43.18%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio14.17

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-18.0M$-18.0M$-21.0M$-27.0M$-38.0M
Net Profit$-24.0M$-18.0M$-21.0M$-26.0M$-39.0M
EPS$-1.93$-0.96$-0.88$-0.76$-1.03
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$31.0M$26.0M$15.0M$35.0M$86.0M
Total Liabilities$12.0M$16.0M$15.0M$3.0M$6.0M
Cash$21.0M$25.0M$15.0M$33.0M$81.0M
Borrowings$10.0M$12.0M$8.0M$0$0

Latest News

Eupraxia Pharmaceuticals Announces Executive Leadership Changes MT Newswires · Jul 13, 2026 Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth GlobeNewswire · Jul 13, 2026 Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization GlobeNewswire · Jul 7, 2026 Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders GlobeNewswire · Jun 19, 2026 Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-14.0M$-16.0M$-30.0M$-29.0M
Investing Cash Flow$-12.0M$10.0M$0$0$-1.0M
Financing Cash Flow$0$0$4.0M$0$0
Net Cash Flow$16.0M$6.0M$1.0M$14.0M$47.0M
Free Cash Flow$-12.0M$-15.0M$-16.0M$-30.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.32
EV / EBITDA-3.76
FCF Yield-14.05%
Quick Ratio16.00
Interest Coverage0.00
Return 1Y24.51%
Return 3Y—
Return 5Y—

Ownership

Insiders Held14.22%
Institutions Held41.96%
Institutions Float Held48.92%
Institutional HolderSharesReport Date
Beutel, Goodman & Company Ltd3,666,4652026-03-31
Affinity Asset Advisors, Llc1,589,0052026-03-31
Balyasny Asset Management LP1,350,0002026-03-31
Vivo Capital, LLC1,350,0002026-03-31
Scotia Capital Inc.1,342,1782026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARDAardvark Therapeutics, Inc. $4.76 +1.06% -1.55 $104.17M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IVAInventiva S.A. $4.47 +1.59% -2.04 $232.36M 0.00%
MDWDMediWound Ltd. $12.54 +0.97% -8.45 $161.09M 0.00%
NAUTNautilus Biotechnology, Inc. $2.25 +23.63% -4.36 $286.32M 0.00%

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is led by CEO James A. Helliwell, employs 33 people, headquartered in CA, publicly traded since 2024.

Eupraxia Pharmaceuticals Inc. (EPRX) stock trades at $7.46 with a market capitalization of $249.76M. The stock is valued at a price-to-earnings (P/E) ratio of -7.10, price-to-book of 3.66, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.25 and $9.32, and currently trades 20.0% below its 52-week high.

On profitability, Eupraxia Pharmaceuticals Inc. generates a return on equity (ROE) of -45.29%, return on capital employed of -43.18%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides